Form 4: Y-mAbs Therapeutics Chief Business Officer Exercises Stock Options, Boosts Direct Shareholding

Thomas Gad, Chief Business Officer and Director of Y-mAbs Therapeutics, Inc., exercised employee stock options to acquire 103,000 shares of common stock at $2 per share, significantly increasing his direct beneficial ownership.

Summary

• Thomas Gad, the Chief Business Officer and a Director of Y-mAbs Therapeutics, Inc. (YMAB), executed an employee stock option exercise.
• On June 3, 2025, Mr. Gad acquired 103,000 shares of Y-mAbs Therapeutics common stock.
• The exercise price for these shares was $2 per share.
• Following this transaction, Mr. Gad's direct beneficial ownership of common stock increased to 305,721 shares.
• He also maintains indirect beneficial ownership of 67,681 shares through GAD Enterprises LLC and 60,000 shares through his children.
• The exercised stock option, which allowed the purchase of 103,000 shares, had an expiration date of June 10, 2025, and was fully vested by June 10, 2019.

Sentiment

Score: 7

Explanation: The exercise of stock options by a key executive to acquire a significant number of shares is generally viewed positively as it indicates confidence in the company's future value. While a routine transaction, it adds to insider ownership, which can be a bullish signal for investors.

Positives

• A key insider, Chief Business Officer and Director Thomas Gad, increased his direct ownership by acquiring 103,000 shares, signaling confidence in the company's future.
• The exercise of stock options by an executive typically indicates a belief in the company's long-term value, especially if the current market price is above the exercise price of $2.

Future Outlook

This Form 4 filing reports a completed insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance, strategic plans, or financial outlook.

Industry Context

This filing is a routine insider transaction report common across all industries, including the biotechnology/pharmaceutical sector. It reflects an individual executive's equity activity within Y-mAbs Therapeutics, Inc., rather than broader industry trends or competitive dynamics.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies.
• The exercise of stock options by an executive is a common component of compensation structures in the biotechnology industry and other sectors.
• Without specific market price data for YMAB or details on other executives' recent transactions within comparable biotechnology companies, a direct comparison to industry-specific benchmarks for insider buying/selling sentiment is not possible from this document alone.

Related Party Transactions

• The transaction involves an executive acquiring shares from the company through an employee stock option plan, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The increase in insider ownership may be perceived as a positive signal of management's confidence in the company's future performance and alignment of interests.
• Employees: The exercise of employee stock options is a standard component of executive compensation, potentially reinforcing the value of equity-based incentives within the company.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, Form 4, Insider Transaction, Stock Option Exercise, Beneficial Ownership, Thomas Gad, Chief Business Officer, Director, Equity Acquisition